Home » GlaxoSmithKline Accelerates Review of Exelixis’ XL880
GlaxoSmithKline Accelerates Review of Exelixis’ XL880
Exelixis, Inc. announced that it has agreed to a request from GlaxoSmithKline (GSK) to initiate its review of XL880 before the compound reaches proof-of-concept.
PR Newswire
Upcoming Events
-
07May
-
14May
-
30May